BioSpace News Archive

Debiopharm, a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, announced their participation in the keynote panel and antibiotic development track sessions at the 2023 World AMR conference from September 7th – 8th, 2023.

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis, announced the first commercial cases of the MISHA™ Knee System, an implantable shock absorber for the knee.

Hoth Therapeutics, Inc. today announced that it has completed its analysis of the data from its Phase 1b clinical trial of BioLexa as a therapeutic for atopic dermatitis.

Switch Therapeutics today announced that Dee Data, Ph.D., Co-Founder and CEO of Switch Therapeutics, will present a corporate overview at the Morgan Stanley 21st Annual Global Healthcare Conference.

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, at the Lotte New York Palace Hotel.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Gibco CTS Detachable Dynabeads (CTS Detachable Dynabeads)*, its next-generation platform of Dynabeads with the first active release mechanism of its kind for clinical trial and commercial manufacturing use.

Partnership will leverage Gustave Roussy’s tumor samples and Veracyte’s Biopharma Atlas multi-omic database and machine learning capabilities.

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced its participation in the upcoming investor conferences.

Inozyme Pharma, Inc. today announced that it granted stock options to a new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan.

ThermoGenesis Holdings, Inc. today announced that Chris Xu , Ph.D., Chief Executive Officer, will present a company overview on Wednesday, September 13, at 4:30 pm ET.